A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
about
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayPolymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health StudyPrevention of fatal hepatic complication in schistosomiasis by inhibition of CETPUnique features of high-density lipoproteins in the Japanese: in population and in genetic factorsJTT-705: is there still future for a CETP inhibitor after torcetrapib?Genetic determinants of human health span and life span: progress and new opportunitiesAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionCholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men.Dalcetrapib: a review of Phase II data.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Genetic causes of high and low serum HDL-cholesterol.Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterolCETP inhibitors and cardiovascular disease: Time to think again.Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B)Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study.Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.Molecular regulation of HDL metabolism and function: implications for novel therapies.Genetic determinants of exceptional human longevity: insights from the Okinawa Centenarian Study.Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.Torcetrapib/atorvastatin combination therapy.Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria.HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications.Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective.Origins of intestinal ABCA1-mediated HDL-cholesterol.Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis.Concentration polarization of high-density lipoprotein and its relation with shear stress in an in vitro model.Is high HDL cholesterol always good?Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.Effects of the Cynanchum wilfordii Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic RatsDyslipidemia and cardiovascular disease: a series of epidemiologic studies in Japanese populations.ABC transporters, atherosclerosis and inflammation.Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles.
P2860
Q24323992-EC98C9FE-C11B-4135-9925-2FFFF73203DDQ24649155-84CE15A9-3B07-4658-9232-716263BBD181Q27011500-38249C55-601A-4829-967A-E40D84C4C54BQ28085611-9D9F7734-91BD-488A-879A-4250C77154F9Q28294797-490F99C2-2587-48EC-B9FC-0B7DA96BD1D8Q28469271-D3D05B2F-3429-4941-8F44-4BA21BB04BFDQ29999973-65A7F019-05D8-4A3B-B17F-D2278E0331A9Q30436835-91489192-3095-44E3-8594-1210585FD36BQ33577236-FE763A5D-9C75-49DD-B135-C91FDBD8711CQ33590777-F87F82E0-589F-4796-B8E1-A2E814B9DA0CQ33639433-7C5C3035-C991-4A20-89F7-3EF834402A30Q33993060-30EA5E52-3156-43D7-BF4C-B1300233CF3FQ34102781-8064A202-3E74-4BA0-9FC2-F61AE35B1111Q34109100-193D5284-0880-4FA7-B143-CF90A01A9034Q34120778-35EDF050-F909-4854-A203-2C929D479C54Q34253290-33E053F9-CCAF-4908-BD4F-1C9BB7A01950Q34297063-374ACD52-BE53-4E25-BFA3-FBA5C846C707Q34441411-3F93F6C3-7FE9-48BC-A78C-BF0D985474FBQ34493756-1272DA1D-E2DF-471D-978B-67B50B41A9DEQ34581693-2144B89D-6B8E-41DC-AAAF-4560F0CDA82EQ34628218-C5058FAF-CADA-4AA8-9F90-6117F1494525Q35191066-BAD1E95F-0B36-49E1-9E21-AC6D15017D62Q35675097-3BF4DEA3-1332-446E-9F93-C1FFB60FFD6DQ35895453-397A4409-014A-41E3-A436-64DAB98574ADQ35928736-EB8009E7-0C80-4626-82B7-3DA8E98EB484Q36197709-9DCA35C4-3DC3-4084-907A-AE492126B88BQ36265996-31DED9F2-DF3D-47C0-9348-B54E7CE7CE75Q36469056-DABAAD94-C84A-4CEA-8C6B-F6048023DCC0Q36796655-059A043D-8735-4126-8909-0138D7759097Q36916850-4D4765E6-B813-4BB1-ABE0-354D2CE24210Q36971289-84207BA8-8979-40FA-9069-A541E26EFCE1Q37179542-54EE01FC-EDA8-440E-8547-656332F0A9F5Q37343533-855B64F4-4065-4238-A56C-84482FC5B432Q37351659-FD86920E-07E1-40AA-80B4-2D6191D1D751Q37456662-5F63115A-D4D1-4030-A64B-CFEBFC6EF398Q37481465-C5753CDF-275F-410D-B7B4-CCC26C7707E9Q37511032-ABD72889-1706-42C8-8E5A-7A458A49371AQ37688500-6BA796F9-8BAA-4407-903D-1EA776A199ADQ37707402-6EA0335A-D665-4CAE-B6CF-194CF9FA9911Q37864609-CCC984CB-E766-40AE-99EA-C1DF9E8D565F
P2860
A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
A prospective study of HDL-C a ...... y heart disease in the elderly
@ast
A prospective study of HDL-C a ...... y heart disease in the elderly
@en
A prospective study of HDL-C a ...... y heart disease in the elderly
@en-gb
A prospective study of HDL-C a ...... y heart disease in the elderly
@nl
type
label
A prospective study of HDL-C a ...... y heart disease in the elderly
@ast
A prospective study of HDL-C a ...... y heart disease in the elderly
@en
A prospective study of HDL-C a ...... y heart disease in the elderly
@en-gb
A prospective study of HDL-C a ...... y heart disease in the elderly
@nl
prefLabel
A prospective study of HDL-C a ...... y heart disease in the elderly
@ast
A prospective study of HDL-C a ...... y heart disease in the elderly
@en
A prospective study of HDL-C a ...... y heart disease in the elderly
@en-gb
A prospective study of HDL-C a ...... y heart disease in the elderly
@nl
P2860
P921
P3181
P1476
A prospective study of HDL-C a ...... y heart disease in the elderly
@en
P2093
J. D. Curb
P2860
P2880
P304
P3181
P356
10.1194/JLR.M300520-JLR200
P407
P577
2004-02-16T00:00:00Z